Status:
COMPLETED
Copeptin: Disease Severity Indicator
Lead Sponsor:
Berker Okay
Conditions:
Lower Respiratory Tract and Lung Infections
Ventilator Lung
Eligibility:
All Genders
1-5 years
Phase:
NA
Brief Summary
Copeptin serves as a biomarker emanating from the pituitary gland, functioning as the precursor to arginine vasopressin (AVP). Its role in the regulation of endothelial dysfunction, inflammation, and ...
Eligibility Criteria
Inclusion
- Being diagnosed with pneumonia,
- The family must have given informed consent for the study.
Exclusion
- Individuals with underlying lung conditions (such as cystic fibrosis, bronchopulmonary dysplasia, asthma, bronchiectasis, tuberculosis),
- Individuals with underlying chronic illnesses (inclusive of heart, kidney, liver, gastrointestinal, and endocrine disorders),
- Individuals with obesity or malnutrition,
- Individuals with hyponatremia detected in their tests,
- Individuals with signs of dehydration,
- Individuals with a history of hospitalization within the last 72 hours.
Key Trial Info
Start Date :
April 12 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 2 2023
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT06211985
Start Date
April 12 2023
End Date
November 2 2023
Last Update
May 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UHS Haseki Training and Research Hospital
Istanbul, Sultangazi, Turkey (Türkiye), 34304